A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)

Inclusion criteria: * Body Mass Index (BMI) between 18 and 32, inclusive * Clinical laboratory tests within normal limits * Free of any clinically significant disease that would interfere with the study evaluations * Screening 12-lead electrocardiogram (ECG) conduction intervals within gender-specific normal range * Vital sign measurements within the following ranges: oral body temperature, 35.0°C to 37.5°C; systolic blood pressure, 90 to 140 mmHg; diastolic blood pressure, 45 to 90 mmHg; pulse rate, 40 to 100 beats per minute * Female participants must be postmenopausal, surgically sterile, abstinent, or using medically accepted method of contraception for 3 months prior to the screening period, during the trial, and for 2 months after stopping the trial. Non-vasectomized men must agree to use acceptable contraception or to abstain from sexual intercourse during the trial and for 3 months after stopping the medication Exclusion Criteria: * Female participants who are pregnant, intend to become pregnant (within 3 months of ending the study), or are breastfeeding * History of coagulation disorder(s), thrombocytopenia, bleeding tendency, ulcers, or gastrointestinal bleeding * History of cardiac abnormalities including clinically relevant ECGs, frequent palpitations or syncopal episodes * Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any drug * History of any infectious disease within 4 weeks prior to drug administration * Positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV) * Positive screen for drugs with a high potential for abuse * History of alcohol or drug abuse in the past 2 years * Blood donation in the past 60 days * Previous treatment with SCH 530348 * Currently participating in another clinical study or has participated in a clinical study within 30 days * Demonstrated allergic reactions * Smokes more than 10 cigarettes or equivalent tobacco use per day * History of malignancy * Has received any protocol-defined treatment which could interfere with ability to participate in the trial